` OCS (Oculis Holding AG) vs ICEX Main Comparison - Alpha Spread

O
OCS
vs
I
ICEX Main

Over the past 12 months, OCS has significantly outperformed ICEX Main, delivering a return of +10% compared to the ICEX Main's 10% drop.

Stocks Performance
OCS vs ICEX Main

Loading
OCS
ICEX Main
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OCS vs ICEX Main

Loading
OCS
ICEX Main
Difference
www.alphaspread.com

Performance By Year
OCS vs ICEX Main

Loading
OCS
ICEX Main
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Oculis Holding AG vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Oculis Holding AG
Glance View

Market Cap
816.8m ISK
Industry
Pharmaceuticals

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

OCS Intrinsic Value
2 346.33 ISK
Overvaluation 10%
Intrinsic Value
Price
O
Back to Top